Last updated: February 17, 2026
Overview of the Drug
NDC 43598-0746 corresponds to Tadalafil, marketed under brand names such as Cialis. It is used primarily for the treatment of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). Tadalafil is available in various formulations, including oral tablets with strengths ranging from 2.5 mg to 20 mg.
Market Size and Growth Drivers
-
Global Market Value: The erectile dysfunction therapeutics market is projected to reach approximately $6.3 billion by 2027, growing at a compound annual growth rate (CAGR) of 4.2% (Source: Fortune Business Insights [1]).
-
US Market Size: The US accounts for around 40% of global ED drug sales, with an estimated market value exceeding $2.5 billion in 2022 (Source: IQVIA [2]).
-
Key Drivers:
- Increasing prevalence of ED linked to aging populations and rising comorbid conditions.
- Expanding indications for tadalafil, including BPH and PAH.
- Continued acceptance of oral ED therapies.
- Patent expirations leading to generic entries.
Competitive Landscape
-
Brand Drugs: Cialis remains a leading brand with broad physician familiarity and established marketing channels.
-
Generics: Multiple generic manufacturers hold FDA approval for tadalafil, leading to significant price competition.
-
Market Share Dynamics: The introduction of generics has reduced brand drug prices by approximately 30%-50%, with recent formulations and patent cliffs further accelerating price reductions.
Price Trends and Projections
| Year |
Average Wholesale Price (AWP) for 30-count, 20 mg tablets (USD) |
Notes |
| 2022 |
$5.50 per tablet |
Reflects current branded price effects |
| 2023 |
$4.50 per tablet |
Entry of multiple generics; competition intensifies |
| 2024 |
$3.80 per tablet |
Continued price erosion |
| 2025 |
$3.20 per tablet |
Market stabilizes; standardization observed |
| 2026 |
$2.90 per tablet |
Generic market dominance persists |
| 2027 |
$2.50 per tablet |
Predicted price plateau under competitive pressures |
Price decline factors:
- Increased generic penetration diminishes brand premium.
- Competition from authorized generics.
- Federal and state pharmacy rebate programs favor lower prices.
- Insurance coverage influences net prices more than list prices.
Market Entry and Patent Status
- Original patent protection expired in September 2017 in the US.
- Several patent litigations and settlements clarified generic entry timelines.
- Current available formulations for tadalafil are predominantly generics, with minimal brand prescriptions.
Pricing for Pharmaceutical Suppliers and Payers
- Brands typically retail at $10–$15 per tablet.
- Generics range from $2.50 to $5 per tablet at wholesale.
- Payers, via pharmacy benefit managers (PBMs), secure significant discounts, often reducing costs 50%-70% relative to list prices.
Regulatory and Policy Impact
- FDA approvals for generics confirmed bioequivalence, enabling widespread market access.
- Policies promoting biosimilar and generic use accelerate price declines.
- Drug formularies favor lower-cost generics, influencing patient access.
Fiscal Impact and Investment Considerations
- Current generics’ dominance suggests diminishing revenue prospects for brand-driven sales.
- Companies investing in new formulations or combo therapies may find growth opportunities.
- Price erosion expected to continue over the next three years unless new indications or formulations emerge.
Key Takeaways
- NDC 43598-0746 (tadalafil) market is mature with high generic penetration.
- Prices are declining, with projections indicating a decline to roughly $2.50 per tablet by 2027.
- The market size remains substantial due to broad indications and demographic drivers.
- Competition, patent landscape, and regulatory policies heavily influence future pricing.
- Investment in innovative formulations or new indications offers growth potential amid pricing pressures.
FAQs
-
How quickly are tadalafil prices declining?
Prices for generic tadalafil have decreased approximately 20–30% annually since patent expiration, with a slowdown expected after 2025.
-
Are there new formulations of tadalafil in development?
Yes. Several companies explore long-acting or combination formulations, potentially impacting future pricing and market share.
-
What is the outlook for branded tadalafil sales?
Branded sales are declining due to generics, but small niches or specialty indications (e.g., PAH) may sustain some revenue.
-
How do insurance policies influence retail pricing?
Insurance and PBMs significantly negotiate discounts, reducing patient out-of-pocket costs and impacting manufacturer revenues.
-
Is the market saturated?
Yes. The market for ED treatments, including tadalafil, is saturated with generics, leading to limited room for price increases or market expansion outside new indications.
Sources
[1] Fortune Business Insights, Erectile Dysfunction Drugs Market Analysis, 2022-2027.
[2] IQVIA, National Prescription Audit, 2022.
